
Bayer Pharma France sells generics business to Teva

Leverkusen – Bayer Pharma France S.A., Puteaux Ced x, has sold its „Bayer Classics“ generics business including the production site in Sens to Teva Pharmaceutical Industries Ltd. for a purchase price of Euro 97 million. Teva, headquartered in Israel, is among the largest generic pharmaceutical companies in the world. The transaction is expected to be completed during the second quarter of 2002.

For Bayer Pharma France this agreement represents the best development opportunity for these two activities – Bayer Classics and the production site. Bayer Classics has become the 3rd generic’s laboratory in France.

“This transaction is reflecting an overall Bayer Pharma strategy to concentrate on the core business of pharmaceutical innovation,” said Wolfgang Plischke, General Manager of Bayer AG’s Pharmaceuticals Business Group. „Today,“ he continued, „the generic business does not belong to the core business outlined in Bayer’s future corporate strategy.”

Leverkusen, April 4, 2002

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F).The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.